Abstract

Abstract Since 2002, beta coronaviruses (CoV) have caused three zoonotic outbreaks, SARS-CoV in 2002–2003, MERS-CoV in 2012, and the newly emerged SARS-CoV-2 in late 2019. However, little is currently known about the biology of SARS-CoV-2. Here, using SARS-CoV-2 S protein pseudovirus system, we confirm that human angiotensin converting enzyme 2 (hACE2) is the receptor for SARS-CoV-2, find that SARS-CoV-2 enters 293/hACE2 cells mainly through endocytosis, that PIKfyve, TPC2, and cathepsin L are critical for entry, and that SARS-CoV-2 S protein is less stable than SARS-CoV S. Polyclonal anti-SARS S1 antibodies T62 inhibit entry of SARS-CoV S but not SARS-CoV-2 S pseudovirions. Further studies using recovered SARS and COVID-19 patients’ sera show limited cross-neutralization, suggesting that recovery from one infection might not protect against the other. Our results present potential targets for development of drugs and vaccines for SARS-CoV-2.

Keywords

VirologyNeutralizationGlycoproteinSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BiologyCoronavirusViral entryPolyclonal antibodiesAntibodyMiddle East respiratory syndrome coronavirusVirusBetacoronavirusCoronavirus disease 2019 (COVID-19)ImmunologyMedicineMolecular biologyViral replication

Affiliated Institutions

Related Publications

Publication Info

Year
2020
Type
article
Volume
11
Issue
1
Pages
1620-1620
Citations
3353
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

3353
OpenAlex

Cite This

Xiuyuan Ou, Yan Liu, Xiaobo Lei et al. (2020). Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nature Communications , 11 (1) , 1620-1620. https://doi.org/10.1038/s41467-020-15562-9

Identifiers

DOI
10.1038/s41467-020-15562-9